$PRME News

Prime Medicine (NASDAQ:PRME) Q1 Results Show Revenue Miss and Narrower Loss as Key Pipeline Milestones Loom

Prime Medicine Q1 EPS $(0.28) Misses $(0.25) Estimate, Sales $856.000K Miss $1.065M Estimate

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine Option Alert: Mar 20 $4 Calls Sweep (5) near the Ask: 2055 @ $0.4 vs 2056 OI; Earnings 3/10 Before Open [est] Ref=$4.03

Prime Medicine Option Alert: Mar 20 $4 Calls Sweep (5) near the Ask: 2055 @ $0.4 vs 2056 OI; Earnings 3/10 Before Open [est] Ref=$4.03

Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates

Favourable Signals For Prime Medicine: Numerous Insiders Acquired Stock

Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases

Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data

LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6